ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 827,24
0,72%
Dow Jones
44 025,81
1,24%
DAX
21 281,28
1,14%
Brent Oil
79,125
0,48%
Bitcoin
105 069,00
-1,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ovid Therapeutics Inc (OVID)

  7. Ovid Therapeutics Inc (OVID) Actualités

OVID

Ovid Therapeutics (OVID)

Ovid Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OVID
DateHeureSourceTitreSymboleSociété
16/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
02/12/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual MeetingNASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
12/11/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
31/10/202413h00GlobeNewswire Inc.Ovid Therapeutics to Host Investor EventNASDAQ:OVIDOvid Therapeutics Inc
26/09/202414h00GlobeNewswire Inc.Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinNASDAQ:OVIDOvid Therapeutics Inc
11/09/202423h36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
11/09/202414h00GlobeNewswire Inc.Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthNASDAQ:OVIDOvid Therapeutics Inc
04/09/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
13/08/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
08/08/202414h00GlobeNewswire Inc.Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerNASDAQ:OVIDOvid Therapeutics Inc
30/07/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming August Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
23/07/202414h00GlobeNewswire Inc.Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsNASDAQ:OVIDOvid Therapeutics Inc
10/07/202414h00GlobeNewswire Inc.eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant SeizuresNASDAQ:OVIDOvid Therapeutics Inc
01/07/202414h00GlobeNewswire Inc.Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsNASDAQ:OVIDOvid Therapeutics Inc
17/06/202412h55GlobeNewswire Inc.Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for SoticlestatNASDAQ:OVIDOvid Therapeutics Inc
14/05/202423h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OVIDOvid Therapeutics Inc
14/05/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
13/05/202413h00GlobeNewswire Inc.Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:OVIDOvid Therapeutics Inc
04/04/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:OVIDOvid Therapeutics Inc
08/03/202414h24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OVIDOvid Therapeutics Inc
08/03/202414h00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
28/02/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:OVIDOvid Therapeutics Inc
14/02/202417h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OVIDOvid Therapeutics Inc
06/02/202414h00GlobeNewswire Inc.Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:OVIDOvid Therapeutics Inc
01/12/202313h30GlobeNewswire Inc.Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)NASDAQ:OVIDOvid Therapeutics Inc
16/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OVIDOvid Therapeutics Inc
15/11/202322h11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OVIDOvid Therapeutics Inc
03/11/202321h08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OVIDOvid Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OVID

Dernières Valeurs Consultées

BIT
UC6JXB
Unicredit Bank
BIT
UC1C4V
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés